Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiovascular Risks for Diabetes Patients, Even for Those With Controlled Cholesterol Levels, at Annual American Diabetes Association (ADA) Meeting
Approximately 10 Million People with Diabetes Are at Elevated Risk of Cardiovascular Disease1,2
In a release issued under the same headline earlier today by
“We have learned through research that cholesterol and diabetes management is not enough to effectively treat cardiovascular disease in patients with diabetes and other risk factors,” said
Association Between Triglycerides and Residual Cardiovascular (CVD) Risk in Patients with Type 2 Diabetes and Established CVD: An Analysis of the BARI2D Trial, Abstract 1472-P, Embargoed Until
Neha J. Pagidipati, M.D., MPH; Ann Marie Navar, M.D., Ph.D.; Hillary Mulder, M.S.; Daniel Wodjyla, M.S.; Sephy Philip, RPh, PharmD; Craig Granowitz, M.D., Ph.D.; Eric D. Peterson, M.D., MPH.
Long-term Statin Persistence is Poor Among High-Risk Patients with Baseline Diabetes: A Real-World Administrative Claims Analysis of the Optum Research Database, Abstract 616-P, Embargoed Until
Peter P. Toth, M.D., Ph.D., Craig Granowitz, M.D., Ph. D. Michael Hull, MS; Sephy Philip, RPh, PharmD.
Moderated Poster Session
Eicosapentaenoic Acid (
- Samuel, C.R. Sheratt, B.S.; R. Preston Mason Ph.D.
About Cardiovascular Disease
Worldwide, cardiovascular disease (CVD) remains the
Multiple primary and secondary prevention trials have shown a significant reduction of 25% to 35% in the risk of cardiovascular events with statin therapy, leaving significant persistent residual risk despite the achievement of target LDL-C levels.5
Beyond the cardiovascular risk associated with LDL-C, genetic, epidemiologic, clinical and real-world data suggest that patients with elevated triglycerides (TG) (fats in the blood), and TG-rich lipoproteins, are at increased risk for cardiovascular disease. 6,7,8,9
Availability of Other Information About Amarin
Investors and others should note that
1 Fan W, Philip S., Granowitz C, Toth P, Wong N. Prevalence and Predictors of Residual Hypertriglyceridemia According to Statin Use in US Adults with Diabetes. Presented at the American Diabetes Association Scientific Sessions,
2 Fan W, Philip S, Granowitz C, et al. Hypertriglyceridemia in statin-treated US adults: the
5 Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330-343.
6 Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016; 118:138-145.
7 Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk.
8 Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease - New insights from epidemiology, genetics, and biology. Circ Res. 2016; 118:547-563.
9 Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014; 384:626–635.
Amarin Contact Information
In U.S.: +1 (908) 325-0735
In U.S.: +1 (908) 719-1315
In U.S.: +1 (646) 378-2992
Source: Amarin Corporation plc